A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT05463731
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Remternetug (IV) — DRUGAdministered IV
- Remternetug (SC) — DRUGAdministered SC
- Placebo — DRUGAdministered IV or SC
Study Details
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
Key Dates
- First listed
- Jul 19, 2022
- Start date
- Aug 1, 2022
- Status verified
- May 2026
- Primary completion
- Apr 24, 2024
- Completion
- May 12, 2026
Study Design
- Enrollment
- 1,667 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Remternetug (IV)Participants will receive remternetug intravenously (IV) Participants will receive remternetug IV during the treatment period, then switch to placebo IV in the extension period.
- Experimental: Remternetug (SC)Participants will receive one of two dosing regimens of remternetug subcutaneously (SC) Participants will receive remternetug SC during the treatment period, then switch to placebo SC in the extension period.
- Placebo Comparator: PlaceboParticipants will receive placebo matching remternetug IV or SC. Participants will receive placebo IV during the treatment period, then switch to remternetug IV in the extension period. Participants will receive placebo SC during the treatment period, then switch to LY3372993 SC in the extension period.
- Experimental: Open-Label Addenda Remternetug (IV)Participants will receive one of six dosing regimens of remternetug IV during the open-label addenda.
- Experimental: Open-Label Addenda Remternetug (SC)Participants will receive one of nine dosing regimens of remternetug SC during the open-label addenda.
Primary Outcome Measure
Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo [ Time Frame: Week 52 ]
Locations (73)
Related coverage on Hipa.ai
- Remternetug Phase 3 TRAILRUNNER-ALZ 1 Study Reaches Primary CompletionMatching Placebo (Remternetug) · Apr 24, 2024 · ClinicalTrials.gov
Find similar trials in Chandler, AZ
By condition
By specialty
Related Studies
- Dominantly Inherited Alzheimer Network (DIAN)Recruiting · Washington University School of Medicine · Jacksonville, Florida
- Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into StudiesRecruiting · Banner Health · Phoenix, Arizona
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesPHASE1/PHASE2 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's DiseaseRecruiting · Douglas Scharre · Columbus, Ohio